BenevolentAI

BenevolentAI is an AI-powered drug discovery platform that helps pharmaceutical companies and researchers identify potential new medicines by analysing biomedical research, scientific literature, and biological data. Designed for research organisations rather than individual users, it supports drug target discovery, disease research, and medicine repurposing to accelerate early-stage drug discovery.

• Built for pharmaceutical companies and research organisations developing new medicines with AI-assisted drug discovery.

• Combines biomedical data, scientific literature, and biological research to identify drug targets and explore medicine repurposing opportunities.

• Supports early-stage drug discovery through research partnerships rather than as a self-service software platform.

• Should be evaluated for data access, collaboration models, research timelines, and pricing before committing to long-term drug discovery projects.

BenevolentAI is best suited to organisations investing in AI-assisted drug discovery, provided its partnership model and research approach align with their scientific and operational requirements.